Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
Saved in:
| Title: | Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials. |
|---|---|
| Authors: | Elliot, Emilie R1 (AUTHOR) emilie.x.elliot@viivhealthcare.com, Polli, Joseph W1 (AUTHOR), Patel, Parul1 (AUTHOR) parul.x.patel@viivhealthcare.com, Garside, Louise2 (AUTHOR), Grove, Richard3 (AUTHOR), Barnett, Vincent4 (AUTHOR), Roberts, Jeremy5 (AUTHOR), Byrapuneni, Sri6 (AUTHOR), Crauwels, Herta7 (AUTHOR), Ford, Susan L4 (AUTHOR), Solingen-Ristea, Rodica Van7 (AUTHOR), Birmingham, Eileen8 (AUTHOR), D'Amico, Ronald1 (AUTHOR), Baugh, Bryan8 (AUTHOR), Wyk, Jean van9 (AUTHOR) |
| Source: | Journal of Infectious Diseases. 7/15/2024, Vol. 230 Issue 1, pe34-e42. 9p. |
| Database: | Environment Complete |
| ISSN: | 00221899 |
|---|---|
| DOI: | 10.1093/infdis/jiad580 |
